Podium to Practice: ASH® 2025 – LEUKEMIA: Venetoclax + Inotuzumab in R/R ALL: Phase I Results
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
ID 645 – Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial
This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.
Studies/trials discussed:
ID 645 – Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.